ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2025
[Progress in Immunotherapy for Pulmonary Lymphoepithelioma Carcinoma].
Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary lymphoepithelioma carcinoma (PLEC), a rare non-small cell lung cancer subtype strongly associated with Epstein-Barr virus (EBV) infection, currently lacks a standardized treatment regimen. Conventional platinum-based systemic chemoradiotherapy remains the primary approach. In recent years, its distinctive pathological features and tumor immune microenvironment have established a compelling rationale for immune checkpoint inhibitors (ICIs). Clinical studies have demonstrated promising efficacy and acceptable safety of ICIs, both as monotherapy and in combination with chemotherapy, in patients with advanced and resectable PLEC. Neoadjuvant immunotherapy has also emerged as a viable strategy to downstage tumors and improve resectability in operable cases. However, the rarity of PLEC has limited the availability of large-scale prospective trials, and current evidence is predominantly derived from retrospective analyses. Key challenges, including predictive biomarkers, mechanisms of immunotherapy, and optimal combination strategies, remain to be addressed. This review systematically summarizes the current clinical evidence, molecular mechanisms, and immune microenvironment characteristics of PLEC, and discusses future research directions. .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.